796851-03-1

Basic information

• Product Name: Pyridine, 2,5-dichloro-4-iodo-
• Synonyms: Pyridine, 2,5-dichloro-4-iodo-;2,5-Dichloro-4-iodopyridine
• CAS NO: 796851-03-1
• Molecular Formula: C₅H₂Cl₂IN
• Molecular Weight: 273.89
• Product Categories: Propidium heterocyclic series
• Mol File: 796851-03-1.mol

Chemical Properties

• Melting Point: 140 ºC
• Boiling Point: 279 ºC
• Flash Point: 122 ºC
• Appearance: /
• Density: 2.129
• Refractive Index: 1.652
• Storage Temp.: Refrigerated.
• CAS DataBase Reference: Pyridine, 2,5-dichloro-4-iodo-(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 2,5-dichloro-4-iodo-(796851-03-1)
• EPA Substance Registry System: Pyridine, 2,5-dichloro-4-iodo-(796851-03-1)

Safety Data

• Hazardous Substances Data: 796851-03-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Pyridine, 2,5-dichloro-4-iodo-, is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure and reactivity allow for the development of new drugs with specific therapeutic properties.
Used in Agricultural Chemical Industry:
Pyridine, 2,5-dichloro-4-iodois also employed as an intermediate in the production of agricultural chemicals, contributing to the development of effective pesticides and other agrochemicals.
Used in Organic Synthesis:
Pyridine, 2,5-dichloro-4-iodo-, is used as a building block in organic synthesis, enabling the creation of a wide range of chemical compounds with diverse applications.
Used in Research and Development Laboratories:
Due to its unique reactivity and versatility, this compound is extensively used in research and development laboratories for exploring new chemical reactions and developing innovative synthetic routes.

InChI:InChI=1/C5H2Cl2IN/c6-3-2-9-5(7)1-4(3)8/h1-2H

Upstream product

• 16110-09-1 2,5 dichloropyridine 

Downstream Products

• 1201935-46-7 2-[(2,5-dichloropyridin-4-yl)amino]-N-methoxy-N-methylbenzamide 
• 1201935-60-5 2-[(2,5-dichloropyridin-4-yl)amino]-6-fluoro-N-methylbenzamide 
• 1061358-83-5 2-[(2,5-dichloropyridin-4-yl)amino]-N-methylbenzamide 
• 1201935-59-2 2-[(2,5-dichloropyridin-4-yl)amino]-3-fluoro-N-methylbenzamide 
• 1201935-41-2 2-[(2,5-dichloro-4-pyridinyl)amino]-N-(methyloxy)benzamide 
• 1201933-80-3 2-((5-chloro-2-((1-(2-oxo-2-(pyrrolidin-1-yl)-ethyl)pyrazol-4-yl)amino)-4-pyridyl)amino)-N-methyl-benzamide 
• 1201933-98-3 2-((5-chloro-2-((1-(4-piperidyl)pyrazol-4-yl)amino)-4-pyridyl)amino)-N-methyl-benzamide 
• 1201933-99-4 2-((5-chloro-2-((1-(1-methyl-4-piperidyl)pyrazol-4-yl)amino)-4-pyridyl)amino)-N-methoxy-N-methyl-benzamide 
• 1201935-43-4 2-[4-[[5-chloro-4-[[2-(methylcarbamoyl)phenyl]amino]pyridin-2-yl]amino]pyrazol-1-yl]acetic acid 
• 1201934-21-5 2-((5-chloro-2-((1,3-dimethylpyrazol-4-yl)amino)-4-pyridyl)amino)-6-fluoro-N-methyl-benzamide 
• 1201933-85-8 2-((5-chloro-2-((5-methoxy-2-methylpyrazol-3-yl)amino)pyridin-4-yl)amino)-N-methylbenzamide 

Relevant articles and documents

POLYSUBSTITUTED PYRIDINE COMPOUND, PREPARATION METHOD, USE AND PHARMACEUTICAL COMPOSITION

The present invention provides a polysubstituted pyridine compound of Formula I, a preparation method, a use and a pharmaceutical composition thereof. The polysubstituted pyridine compound of Formula I according to the present invention has an excellent anti-tumor effect, can inhibit various cell kinases simultaneously, has significantly excellent pharmacokinetic characteristics, and is very suitable for oral and intravenous administration. The pharmaceutical composition according to the present invention can be useful for treating tumors and cancers.

Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity

Medulloblastoma is one of the most prevalent brain tumors in children. Aberrant hedgehog (Hh) pathway signaling is thought to be involved in the initiation and development of medulloblastoma. Vismodegib, the first FDA-approved cancer therapy based on inhibition of aberrant hedgehog signaling, targets smoothened (Smo), a G-protein coupled receptor (GPCR) central to the Hh pathway. Although vismodegib exhibits promising therapeutic efficacy in tumor treatment, concerns have been raised from its nonlinear pharmacokinetic (PK) profiles at high doses partly due to low aqueous solubility. Many patients experience adverse events such as muscle spasms and weight loss. In addition, drug resistance often arises among tumor cells during treatment with vismodegib. There is clearly an urgent need to explore novel Smo antagonists with improved potency and efficacy. Through a scaffold hopping strategy, we have identified a series of novel tetrahydropyrido[4,3-d]pyrimidine derivatives, which exhibited effective inhibition of Hh signaling. Among them, compound 24 is three times more potent than vismodegib in the NIH3T3-GRE-Luc reporter gene assay. Compound 24 has a lower melting point and much greater solubility compared with vismodegib, resulting in linear PK profiles when dosed orally at 10, 30, and 100 mg/kg in rats. Furthermore, compound 24 showed excellent PK profiles with a 72% oral bioavailability in beagle dogs. Compound 24 demonstrated overall favorable in vitro safety profiles with respect to CYP isoform and hERG inhibition. Finally, compound 24 led to significant regression of subcutaneous tumor generated by primary Ptch1-deficient medulloblastoma cells in SCID mouse. In conclusion, tetrahydropyrido[4,3-d]pyrimidine derivatives represent a novel set of Smo inhibitors that could potentially be utilized to treat medulloblastoma and other Hh pathway related malignancies.

Deprotonative metalation of chloro- and bromopyridines using amido-based bimetallic species and regioselectivity-computed CH acidity relationships

A series of chloro- and bromopyridines have been deprotometalated by using a range of 2,2,6,6-tetramethylpiperidino-based mixed lithium-metal combinations. Whereas lithium-zinc and lithium-cadmium bases afforded different mono- and diiodides after subsequent interception with iodine, complete regioselectivities were observed with the corresponding lithium-copper combination, as demonstrated by subsequent trapping with benzoyl chlorides. The obtained selectivities have been discussed in light of the CH acidities of the substrates, determined both in the gas phase and as a solution in THF by using the DFT B3LYP method.

PYRIDINE COMPOUNDS

The present invention relates to compounds that inhibit of focal adhesion kinase function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases such as cancer.

PYRIDINE COMPOUND, PESTICIDAL COMPOSITION AND METHOD OF CONTROLLING PEST

A pyridine compound represented by the following general formula (1); the pyridine compound in which R1 is a C1-C3 fluoroalkyl group or a C1-C3 fluoroalkoxy group; the pyridine compound in which R2 is a hydrogen atom; the pyridine compound in which R2 is a group represented by Q1; a pesticidal composition containing the pyridine compound as an active ingredient; and a method of controlling a pest including applying an effective amount of the pyridine compound to the pest or a place where the pest inhabits, are provided.

INHIBITORS OF FOCAL ADHESION KINASE

The invention provides inhibitors of focal adhesion kinase, an enzyme involved in the attachment of the cytoskeleton of a cell to an extracellular matrix, which has been implicated in processes such as cell migration, cell proliferation, and cell survival. The inhibitors are derivatives of a 5-substituted 2,4-diaminopyridine wherein the substituents are as defined herein. The invention also provides a method of using the inhibitors in treatment of cancer, and methods of preparation of the inhibitors by use of coupling reactions.

Deprotonation of chloropyridines using lithium magnesates

Chloropyridines are deprotonated using lithium magnesates. 4-Chloropyridine was deprotonated on treatment with 1/3 equiv of the highly coordinated magnesate Bu3(TMP)MgLi2 in THF at -10°C, as evidenced by trapping with I2. The use of Bu(TMP)2MgLi in Et 2O allowed the reaction of 2-chloropyridine, giving the 3-functionalized derivative as the main product. Mixtures of 3- and 4-functionalized derivatives were obtained when 2,6-dichloropyridine was involved in the reaction. Performing the reaction on 3-chloropyridine with lithium magnesates in THF, either the 4,4′-dimer or the 4-iodo derivative was formed after quenching by I2, the former using 1/3 equiv of Bu2(TMP)MgLi and the latter using 1 equiv of (TMP)3MgLi. Similar results were observed with 3,5-dichloropyridine, 2,5-dichloropyridine and 3-chloro-2-fluoropyridine. 1,2-Migration of the lithium arylmagnesate formed by deprotonation was proposed to justify the dimers formation.